These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
142 related articles for article (PubMed ID: 36070450)
1. An Evaluation of Sexual Function in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia in Men Treated with the Temporarily Implanted Nitinol Device. Elterman D; Alshak MN; Martinez Diaz S; Shore N; Gittleman M; Motola J; Pike S; Hermann C; Terens W; Kohan A; Gonzalez R; Katz A; Schiff J; Goldfischer E; Grunberger I; Tu L; Kaminetsky J; Chughtai B J Endourol; 2023 Jan; 37(1):74-79. PubMed ID: 36070450 [No Abstract] [Full Text] [Related]
2. The iTind Temporarily Implanted Nitinol Device for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: A Multicenter, Randomized, Controlled Trial. Chughtai B; Elterman D; Shore N; Gittleman M; Motola J; Pike S; Hermann C; Terrens W; Kohan A; Gonzalez RR; Katz A; Schiff J; Goldfischer E; Grunberger I; Tu LM; Alshak MN; Kaminetzky J Urology; 2021 Jul; 153():270-276. PubMed ID: 33373708 [TBL] [Abstract][Full Text] [Related]
3. Urinary and sexual function after treatment with temporary implantable nitinol device (iTind) in men with LUTS: 6-month interim results of the MT-06-study. De Nunzio C; Cantiello F; Fiori C; Crocerossa F; Tognoni P; Amparore D; Baldassarri V; Elbers JR; Sancha FG; Porpiglia F World J Urol; 2021 Jun; 39(6):2037-2042. PubMed ID: 32851439 [TBL] [Abstract][Full Text] [Related]
4. Second generation of temporary implantable nitinol device (iTind) in men with LUTS: 2 year results of the MT-02-study. Kadner G; Valerio M; Giannakis I; Manit A; Lumen N; Ho BSH; Alonso S; Schulman C; Barber N; Amparore D; Porpiglia F World J Urol; 2020 Dec; 38(12):3235-3244. PubMed ID: 32124019 [TBL] [Abstract][Full Text] [Related]
5. Temporarily implanted nitinol device versus prostatic urethral lift for minimally invasive surgical treatment of benign prostatic hyperplasia with lower urinary tract symptoms: a matching-adjusted indirect comparison. Kernen KM; Omar S; Goodnight B; Skodny P; Bruce S; Yu TM Can J Urol; 2023 Oct; 30(5):11676-11685. PubMed ID: 37838995 [TBL] [Abstract][Full Text] [Related]
6. Second-generation of temporary implantable nitinol device for the relief of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a prospective, multicentre study at 1 year of follow-up. Porpiglia F; Fiori C; Amparore D; Kadner G; Manit A; Valerio M; Nicolaas L; Ho BSH; Alonso S; Schulman C; Barber N BJU Int; 2019 Jun; 123(6):1061-1069. PubMed ID: 30382600 [TBL] [Abstract][Full Text] [Related]
7. Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. McVary KT; Gange SN; Shore ND; Bolton DM; Cowan BE; Brown BT; Te AE; Chin PT; Rukstalis DB; Roehrborn CG; J Sex Med; 2014 Jan; 11(1):279-87. PubMed ID: 24119101 [TBL] [Abstract][Full Text] [Related]
8. Erectile and Ejaculatory Function Preserved With Convective Water Vapor Energy Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia: Randomized Controlled Study. McVary KT; Gange SN; Gittelman MC; Goldberg KA; Patel K; Shore ND; Levin RM; Rousseau M; Beahrs JR; Kaminetsky J; Cowan BE; Cantrill CH; Mynderse LA; Ulchaker JC; Larson TR; Dixon CM; Roehrborn CG J Sex Med; 2016 Jun; 13(6):924-33. PubMed ID: 27129767 [TBL] [Abstract][Full Text] [Related]
9. 3-Year results following treatment with the second generation of the temporary implantable nitinol device in men with LUTS secondary to benign prostatic obstruction. Amparore D; Fiori C; Valerio M; Schulman C; Giannakis I; De Cillis S; Kadner G; Porpiglia F Prostate Cancer Prostatic Dis; 2021 Jun; 24(2):349-357. PubMed ID: 33005003 [TBL] [Abstract][Full Text] [Related]
10. The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. Roehrborn CG; Gange SN; Shore ND; Giddens JL; Bolton DM; Cowan BE; Brown BT; McVary KT; Te AE; Gholami SS; Rashid P; Moseley WG; Chin PT; Dowling WT; Freedman SJ; Incze PF; Coffield KS; Borges FD; Rukstalis DB J Urol; 2013 Dec; 190(6):2161-7. PubMed ID: 23764081 [TBL] [Abstract][Full Text] [Related]
11. Sexual function in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: results of a 6-month, randomized, double-blind, placebo-controlled study of tadalafil coadministered with finasteride. Glina S; Roehrborn CG; Esen A; Plekhanov A; Sorsaburu S; Henneges C; Büttner H; Viktrup L J Sex Med; 2015 Jan; 12(1):129-38. PubMed ID: 25353053 [TBL] [Abstract][Full Text] [Related]
13. Preservation of sexual function with the prostatic urethral lift: a novel treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Woo HH; Bolton DM; Laborde E; Jack G; Chin PT; Rashid P; Thavaseelan J; McVary KT J Sex Med; 2012 Feb; 9(2):568-75. PubMed ID: 22172161 [TBL] [Abstract][Full Text] [Related]
14. How I Do It: Temporarily Implanted Nitinol Device (iTind). Elterman D; Gao B; Zorn KC; Bhojani N; Chughtai B Can J Urol; 2021 Aug; 28(4):10788-10793. PubMed ID: 34378517 [TBL] [Abstract][Full Text] [Related]
15. Aquablation of the prostate for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. Hwang EC; Jung JH; Borofsky M; Kim MH; Dahm P Cochrane Database Syst Rev; 2019 Feb; 2(2):CD013143. PubMed ID: 30759311 [TBL] [Abstract][Full Text] [Related]
16. Do Minimally Invasive Benign Prostatic Hyperplasia Treatments Preserve Sexual Function? A Contemporary Review of the Literature. Kim J; Polchert M; Chacko B; Tannenbaum J; Raheem O Curr Urol Rep; 2021 Nov; 22(11):56. PubMed ID: 34727240 [TBL] [Abstract][Full Text] [Related]
17. Impact of Surgery for Benign Prostatic Hyperplasia on Sexual Function: A Systematic Review and Meta-analysis of Erectile Function and Ejaculatory Function. Manfredi C; García-Gómez B; Arcaniolo D; García-Rojo E; Crocerossa F; Autorino R; Gratzke C; De Sio M; Romero-Otero J Eur Urol Focus; 2022 Nov; 8(6):1711-1732. PubMed ID: 35803852 [TBL] [Abstract][Full Text] [Related]
18. Direct effects of tadalafil on lower urinary tract symptoms versus indirect effects mediated through erectile dysfunction symptom improvement: integrated data analyses from 4 placebo controlled clinical studies. Brock GB; McVary KT; Roehrborn CG; Watts S; Ni X; Viktrup L; Wong DG; Donatucci C J Urol; 2014 Feb; 191(2):405-11. PubMed ID: 24096120 [TBL] [Abstract][Full Text] [Related]
19. First- and Second-Generation Temporary Implantable Nitinol Devices As Minimally Invasive Treatments for BPH-Related LUTS: Systematic Review of the Literature. Amparore D; De Cillis S; Volpi G; Checcucci E; Manfredi M; Morra I; Di Dio M; Fiori C; Porpiglia F; Curr Urol Rep; 2019 Jul; 20(8):47. PubMed ID: 31278441 [TBL] [Abstract][Full Text] [Related]
20. The PINNACLE Study: A Double-blind, Randomized, Sham-controlled Study Evaluating the Optilume BPH Catheter System for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Kaplan SA; Moss J; Freedman S; Coutinho K; Wu N; Efros M; Elterman D; D'Anna R; Padron O; Robertson KJ; Lawindy S; Mistry S; Shore N; Spier J; Kaminetsky J; Mazzarella B; Cahn D; Jalkut M; Te A J Urol; 2023 Sep; 210(3):500-509. PubMed ID: 37555604 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]